Did a little reading on T-cells, Dr. June and Novartis this weekend. Do not know if this is accurate but read that Novartis owns 30% of Roche. Novartis new CEO is on a mission to cure cancer with t-cells. Aggressive research and money not a factor. If Peg is needed to progress past blood cancers, I can see Novartis being interested.
Trial design for next Peg trial could be very telling about who is most interested initially.
News 
Market Data 
Discover 
